With snowballing healthcare spending and the emergence of new modalities of treatments, discussions are heating up around revisiting the scope of health coverage on pharmaceuticals, with the Ministry of Finance (MOF) and payers advocating the mantra of “large risks with…
HOME > BUSINESS
BUSINESS
- Takeda to Divest 30 OTC, Non-Core Assets to Swiss Firm
October 16, 2019
- Astellas to Sell 3 Asian Products to Daiichi Sankyo for 9.6 Billion Yen
October 16, 2019
- FDA OKs 1st Schizophrenia Patch Drug: Hisamitsu
October 16, 2019
- Eisai’s Fycompa Gets China Thumbs-Up
October 16, 2019
- No Major Drug Supply Disruption after Typhoon Hagibis
October 16, 2019
- Sakigake-Designated Radiation Therapy Agent Filed in Japan
October 16, 2019
- OrphanPacific to Take Over Marketing Authorization for MSD’s Diazoxide
October 16, 2019
- Sanofi, Kaken to Wind Up Clexane Partnership
October 16, 2019
- After Entresto Flop, Hopes Grow for SGLT2 Inhibitors as HFpEF Treatments
October 16, 2019
- AZ, Sanofi Kick Off Japan PIII for RSV Prevention
October 15, 2019
- MSD Seeking to Trim 250 Jobs in Japan
October 15, 2019
- Japan Ethical Drug Market Forecast at 8.9 Trillion Yen in 2026: Fuji Keizai
October 15, 2019
- Shionogi Signs New Mycobacterial Deal with Hsiri
October 15, 2019
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- All Eyes on Performance of Top-2 Anti-Flu Drugs Xofluza, Inavir as Flu Seasons Approaches
October 11, 2019
- Daiichi Sankyo’s AML Drug Vanflyta Now Available
October 11, 2019
- AZ, Keio Univ. Pair Up to Create Real World Evidence in Healthcare
October 11, 2019
- GSK Japan Ups Recall Level for Zantac to “Class I”
October 10, 2019
- Sosei Bags US$3 Million from Genentech on Nomination of New GPCR Disease Target
October 10, 2019
- Mitsubishi Tanabe Gains Japan, Asian Rights for Viela Bio's Inebilizumab
October 10, 2019
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…